Print Page     Close Window     

SEC Filings

10-K/A
BIOTIME INC filed this Form 10-K/A on 04/02/2018
Entire Document
 
 

 

ONCOCYTE CORPORATION

STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands)

 

   Common Stock  

Accumulated

Other

Comprehensive

   Accumulated  

Total

Shareholders’

 
   Shares   Amount   Loss   Deficit   Equity (Deficit) 
BALANCE AT DECEMBER 31, 2014   18,200   $15,147   $(822)  $(15,399)  $(1,074)
Net loss   -    -    -    (8,735)   (8,735)
Unrealized gain on BioTime shares held as available-for-sale securities   -    -    75    -    75 
Stock-based compensation   -    1,815    -    -    1,815 
Common stock issued to BioTime for extinguishment of debt   1,500    3,300    -    -    3,300 
Common stock issued to investors for cash   1,500    3,300    -    -    3,300 
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest   1,508    3,318    -    -    3,318 
Common stock issued to BioTime for cash   2,711    8,349    -    -    8,349 
Exercise of stock options   3    4    -    -    4 
Fair value of contingently issuable warrant   -    65    -    -    65 
OncoCyte common stock received as a dividend in kind from BioTime   (31)   -    -    -    - 
Transfer of realized loss into equity from sale of BioTime shares   -    (397)   397    -    - 
BALANCE AT DECEMBER 31, 2015   25,391    34,901    (350)   (24,134)   10,417 
Net loss   -    -    -    (11,168)   (11,168)
Unrealized loss on BioTime shares held as available-for-sale securities   -    -    (304)   -    (304)
Stock-based compensation   -    922    -    -    922 
Proceeds from issuance of common stock and warrants, net of discounts and financing costs   3,246    9,777    -    -    9,777 
Exercise of stock options   100    218    -    -    218 
BALANCE AT DECEMBER 31, 2016   28,737    45,818    (654)   (35,302)   9,862 
Net loss   -    -    -    (19,375)   (19,375)
Unrealized loss on BioTime shares held as available-for-sale securities   -    -    (527)   -    (527)
Stock-based compensation   -    1,630    -    -    1,630 
Issuance of common stock upon exercise of 2016 warrants   2,392    7,774    -    -    7,774 
Exercise of stock options   323    610    -    -    610 
Issuance of warrants for inducement to exercise 2016 warrants   -    4,074    -    -    4,074 
Issuance of warrants to Silicon Valley Bank   -    62    -    -    62 
Transfer of realized loss on sale of BioTime shares   -    -    293    -    293 
BALANCE AT DECEMBER 31, 2017   31,452   $59,968   $(888)  $(54,677)  $4,403 

 

The accompanying notes are an integral part of these financial statements.

 

   

© Copyright BioTime, Inc.